None
EN
STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans
['Jason Mast', 'Allison Deangelis', 'Jason Is A General Assignment Reporter', 'With Particular Focus On Genetic Medicine', 'Rare Disease. Confidential Tips Can Be Sent On Signal At', 'Allison Covers What Hot Startups Are Getting Up To', 'Who S Financing Them. She Is Also Co-Host Of The Weekly Biotech Podcast', 'General Assignment Reporter', 'Biotech Startups', 'Venture Capital Reporter']
STAT
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease.
Allison covers what hot startups are getting up to, and who’s financing them.
A company spokesperson declined to say how many employees were laid off, or whether any of the startup’s three-person leadership team would stay on.
AdvertisementThe company appears to have been undercut by Beam Therapeutics, a larger and more established competitor.
Just a month after Aurora launched, Beam announced it was already advancing its own set of custom gene editors for the exact same disease.